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Fungal Infections in Renal Transplant Patients
Asif Khana, c, Elie El-Charabatyb, Suzanne El-Sayeghb
Abstract
Organ transplantation has always been considered to be the standard 
therapeutic interventions in patients with end-stage organ failure. In 
2008, more than 29,000 organ transplants were performed in US. Sur-
vival rates among transplant recipients have greatly improved due to 
better understanding of transplant biology and more effective immuno-
suppressive agents. After transplant, the extent of the immune response 
is influenced by the amount of interleukin 2 (IL-2) being produced 
by the T-helper cells. Transplant immunosuppressive therapy primar-
ily targets T cell-mediated graft rejection. Calcineurin inhibitor, which 
includes cyclosporine, pimecrolimus and tacrolimus, impairs calcineu-
rin-induced up-regulation of IL-2 expression, resulting in increased 
susceptibility to invasive fungal diseases. This immunosuppressive 
state allows infectious complication, leading to a high mortality rate. 
Currently, overall mortality due to invasive fungal infections (IFIs) in 
solid organ transplant recipients ranges between 25% and 80%. The 
risk of IFI following renal transplant is associated with the dosage of 
immunosuppressive agents given, environmental factors and post-
transplant duration. Most fungal infections occur in the first 6 months 
after transplant because of the use of numerous immunosuppressors. 
Candida spp. and Cryptococcus spp. are the yeasts most frequently 
isolated, while most frequent filamentous fungi (molds) isolated are 
Aspergillus spp. The symptoms of systemic fungal infections are non-
specific and early detection of fungal infections and proper therapy are 
important in improving survival and reducing mortality. This article 
will provide an insight on the risk factors and clinical presentation, 
compare variation in treatment of IFIs in renal transplant patients, and 
evaluate the role of prophylactic therapy in this group of patients. We 
also report the course and management of two renal transplant recipi-
ents admitted to Staten Island University Hospital, both of whom de-
veloped pulmonary complications secondary to Aspergillus infection.
Keywords: Renal transplant; Fungal infection; Transplant
Introduction
Renal transplantation has always been considered to be the 
standard therapeutic interventions in patients with end-stage 
organ failure. In 2008, more than 29,000 organ transplants 
were performed in US [1]. Increased immunosuppression, 
multiple organ transplantation as well as environmental fac-
tors are just some of the risk factors involved in this increased 
incidence of invasive fungal infection (IFI) [2]. Survival rates 
among transplant recipients have greatly improved due to bet-
ter understanding of transplant biology and more effective im-
munosuppressive agents.
The Transplant-Associated Infection Surveillance Net-
work conducted a 5-year prospective study among 1,063 organ 
transplant recipients. One thousand two hundred eight were 
diagnosed with IFI. The most common IFIs were invasive can-
didiasis (53%), invasive aspergillosis (IA) (19%), cryptococ-
cosis (8%), non-Aspergillus molds (8%), endemic fungi (5%), 
and zygomycosis (2%) [3].
With the use of more effective immunosuppressors, most 
fungal infection occurs within the first 6 months after trans-
plant [4]. The median time to the onset of infection is also de-
pendent on the causative agents. The median times to the onset 
of candidiasis, aspergillosis, and cryptococcosis after trans-
plant were 103, 184, and 575 days respectively [3].
In the US, each year approximately 15,000 renal trans-
plants are performed, with a 5-year survival rate of > 80% [5]. 
The rate of infection in renal transplant patients during the ini-
tial 3 years after transplant is 46% and is associated with the 
duration and net dosage of immunosuppressive agents given 
[1].
Five percent of all infections in renal transplant recipients 
are fungal in origin [6]. Fungal conidia are being constantly 
inhaled eliminated by innate mechanisms in healthy individu-
als. Aspergillus spores are ubiquitous in the environment and 
may become concentrated in hospital ventilation systems. As-
pergillus was regarded as a weak pathogen, but there has been 
a dramatic increase in the incidence of aspergillosis in the last 
two decades, yet mortality has decreased from 92% in 1990 to 
60% in 1998 [7].
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IA is a life-threatening complication in patients who un-
dergo solid organ transplantation, having an incidence be-
tween 0.5% and 2.2% [8] with a mortality rate of > 70% [9], 
and a high case-fatality rate of up to 88% [10].
Presentations
Renal transplant recipients usually present with vague clinical 
symptoms of infection and early laboratory reveals are normal. 
To improve the prognosis, a high index of suspicion is neces-
sary in renal transplant recipients.
Unexplained fever despite broad-spectrum antibiotic treat-
ment for more than 3 - 6 days, recurring febrile episodes after 
initial defervescence, or the presence of pulmonary infiltrates 
during antibiotic treatment can indicate a fungal infection. 
Early symptoms of invasive pulmonary aspergillosis include 
cough, fever and hemoptysis.
Preventive measures should be taken using sensitive as-
says (e.g. antigen detection and molecular assays) to moni-
tor patients at given interval and stop progression to invasive 
disease. A positive assay will require initiation of therapy and 
reduction in the anti-suppression medication, with frequent 
monitoring of the patient.
To reduce the risk of infection, pre-transplant screening of 
donor and recipient, vaccination, and post-transplant surveil-
lance and prophylaxis are required.
Risk Factors in Renal Transplant Recipients
Aspergillus spores are ubiquitous in the environment. Hospital 
constructions or at adjacent sites predispose the hospital venti-
lation systems to become concentrated with Aspergillus spores 
and may serve as the source micro-epidemics of aspergillosis.
In a retrospective case-control study on 156 transplant 
cases, early-onset IA (i.e., occurred during the first 90 days af-
ter transplantation) was identified in 57% cases and 43% cases 
had late-onset infections (i.e., occurred after 90 days period) 
[11]. This bimodal pattern of infection is suggestive of differ-
ent risk factors between early- and late-onset cases.
The use of vascular amines for > 24 h after surgery, inten-
sive care unit (ICU) readmission, development of renal failure, 
need for hemodialysis, and occurrence of > 1 episode of bacte-
rial infection after transplantation were the major risk factors 
for early-onset IA [11].
Late-onset IA was contributed to age > 50 years, chronic 
impaired graft function, use of immunosuppressive drugs and 
occurrence of an immunosuppression-related neoplasm [11]. 
Other risk factors such as diabetes and prolonged pre-trans-
plant dialysis had also shown to promote serious fungal infec-
tions [12].
Diagnosis
The European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperative Group and the 
National Institute of Allergy and Infectious Diseases Mycoses 
Study Group (EORTC/MSG) Consensus Group defines inva-
sive fungal infection when histological analysis or culture of 
a specimen of tissue taken from a site of disease can reveal 
fungus. In case of Cryptococcus neoformans, a positive result 
of an India ink preparation of CSF or detection of capsular 
antigen in CSF is sufficient [13].
Diagnosis of fungal infection in transplant recipients can 
be very perplexing due to the vague patient symptoms and the 
lack of specificity of blood test or radiologic finding. It is esti-
mated about 30% of the IFI cases at death remain undiagnosed 
or untreated [14]. An elevated creatinine level in RTR indi-
cates a state of chronic rejection and opportunistic infection 
[6]. A combination of various methods and regular screening 
is therefore advisable to ensure that a diagnosis is reached as 
soon as possible.
Tests including cultures from blood, cerebrospinal fluid, 
peritoneal fluid, quantitative tests (such as sandwich enzyme-
linked immunosorbent assays or molecular assays) that direct-
ly detect the protein products or nucleic acids of the organisms 
are needed for routine monitoring of transplant patients [15].
The galactomannan assay can detect aspergillosis before 
symptoms appear, but sensitivity and specificity in solid organ 
transplant patients are lower than in hematological patients 
[16]. A negative result does not rule out the diagnosis of IA 
and repeat testing is recommended.
Having a baseline serum tested and testing biweekly for 
increasing galactomannan antigen levels can monitor thera-
peutic response. False negative results can occur due to decline 
in antigen levels in response to antimicrobial therapy [14].
In addition to routine component of initial evaluation, in-
vasive procedures that provide tissues for culture and histo-
logic testing should be performed early.
Potassium hydroxide wet mount smear is the most sensi-
tive screening test for the rapid detection of fungal elements. 
All tissues from patients with a suspected invasive fungal in-
fection should be stained with a fungal stain such as acridine 
orange, periodic acid-Schiff reaction, Grocott-Gomori methe-
namine silver staining, lectins, and Calcofluor white [15].
Imaging studies are not always useful in helping clinicians 
diagnose fungal infections. Thoracic computed tomographic 
scans, chest radiographs, and abdominal ultrasonography can 
be used to reveal pulmonary infiltrates, hydronephrosis, fun-
gus balls, or perinephric abscesses highly suggestive of trans-
plant failures from infections.
The results of those tests would enable clinicians to in-
dividualize prophylactic antifungal regimens and minimize 
drug-associated toxicity.
Antifungal Treatment in Renal Transplant Re-
cipients
One of the most important goals in the field of transplantation 
is the prevention of fungal infections. The epidemiological 
exposure and immunosuppression state of the patient should 
be determined for individual risk assessment, thereby allow-
ing for the implementation of preventive interventions, taking 
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account of the potential side effects and emerging resistance 
of the antifungal prophylactic strategies. Table 1 displays the 
drugs frequently used to treat renal mycoses [15].
Amphotericin B
Amphotericin B deoxycholate (AmB-D) is a polyene with a 
very broad spectrum of activity, including most yeasts and 
filamentous fungi. For the past four decades, AmB-D has been 
considered to be the standard antifungal agent for treatment of 
IA in severely immunocompromised patients. But more than 
50% of cases have reported nephrotoxicity or infusion-related 
side effects. AmB-D is not recommended as a first-line therapy 
in renal transplant recipients [17].
In a separate study of 239 immunosuppressed AmB-treat-
ed patients (63% of whom had undergone a transplant proce-
dure), S-Cr level doubled from baseline in 53% of patients and 
increased to > 2.5 mg/dL in 29% of patients, whereas 15% 
of patients required dialysis [18]. The risk of nephrotoxicity 
increases with the concurrent use of calcineurin. Other side 
effects include fevers, chills, nausea and vomiting, and hypo-
tension.
Liposomal amphotericin B (L-AmB)
L-AmB is a lipid-associated formulation of the broad-spec-
trum polyene antifungal agent amphotericin B. L-AmB is in-
dicated for the treatment of severe systemic mycoses in which 
nephrotoxicity limits the use of amphotericin B.
It is active against clinically relevant yeasts and molds, in-
cluding Candida spp., Aspergillus spp. and filamentous molds 
such as zygomycetes. Liposomal formulation is also indicated 
for the empirical treatment of presumed fungal infections, in 
whom the fever has failed to respond to broad-spectrum an-
tibiotics and appropriate investigations have failed to define a 
bacterial or viral cause.
A meta-analysis study reported reduction in all-cause mor-
tality for invasive fungal infections by almost 30% by lipid-
associated formulations when compared with AmB-D [19].
In a separate study by Leenders et al demonstrated higher 
efficacy of L-AmB given at 5mg/kg than AmB-D in a study of 
patients with IA [20].
Azole
All azole agents interrupt the cell membrane ergosterol syn-
thesis by fungi by inhibition of cytochrome P450. Elevations 
in hepatic enzyme levels alanine aminotransferase and as-
partate aminotransferase occur with azole therapy. Although 
most patients have asymptomatic elevation of hepatic enzyme 
levels, liver function tests prior to therapy, within the first 2 
weeks after the initiation of therapy, and then every 2 - 4 weeks 
throughout therapy should be performed [21].
Voriconazole
This triazole antifungal agent, with broadened antifungal 
spectrum, is used for opportunistic infections in immunocom-
promised patients. Voriconazole shows good in vitro activity 
against all Candida species, including certain Candida strains 
that are inherently fluconazole-resistant, and strains of Can-
dida albicans that have acquired resistance to fluconazole and 
other yeasts, including Cryptococcus neoformans [21].
Voriconazole should not replace fluconazole or other an-
tifungal agents for treatment of most Candida infections. The 
drug has more side effects and drug interactions than flucona-
zole.
It has also shown activity against Aspergillus, including 
amphotericin B-resistant Aspergillus strains. A large, rand-
omized trial compared standard amphotericin B with voricon-
azole for primary treatment of IA [22]. Of 277 patients who 
had confirmed IA and who received ≥ 1 dose of study drug, 
133 were randomized to receive amphotericin B and 144 were 
randomized to receive voriconazole.
Successful outcomes were noted in 32% of patients in the 
amphotericin B group versus 53% of patients in the voricona-
zole group (95% CI: 10.4 - 32.9). The survival rate was 58% 
in the amphotericin B group when compared to 71% in the 
voriconazole group (P = 0.02). Based on the results voricona-
zole was found to be more effective than amphotericin B and 
likely to become the drug of choice for the primary treatment 
of patients with IA.
It is available in both oral and intravenous formulations 
and the recommended regimen loading dose of 6 mg/kg every 
12 h for two doses, followed by a maintenance dose of 4 mg/kg 
every 12 h. Metabolism of voriconazole occurs via CYP 450 
Table 1.  Drugs Frequently Used to Treat Renal Mycoses Are Listed Below [15]
Type of infection Drug Dosage Duration of treatment
Candiduria Fluconazole 200 - 400 mg/day Several days before and after the  
procedure
Candidemia Fluconazole Loading dose: 800 mg/day, then 400  
mg/day
14 days after first negative blood culture  
result
Invasive aspergillosis Voriconazole 4 mg/kg twice daily Until all signs and symptoms of infection  
have resolved for at least 2 weeks
Cryptococcosis Fluconazole 400 mg/day 6 - 12 months
Mucormycosis Liposomal amphoteracin B 5 mg/kg/day Until patient exhibits a favorable response
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enzyme in the liver and therefore it is necessary to adjust dose 
in patients with hepatic insufficiency [21].
Reversible “disturbance of vision” is the most common 
side effect of voriconazole and occurs in 30% of patients. For-
tunately these symptoms tend to decrease or disappear in spite 
of continued therapy in most patients [21].
In a randomized, double blind, placebo-controlled, crosso-
ver study in kidney transplant recipients with stable renal func-
tion, co-administration of voriconazole in patient receiving 
cyclosporine resulted in increased minimum plasma concen-
tration of cyclosporine by 1.7 folds [23]. The sample size in the 
study was not significant to draw a conclusion.
Therefore it is recommended to decrease the cyclosporine 
dose by half when voriconazole is initiated in patients. Blood 
cyclosporine concentrations should also be monitored and in-
creased if voriconazole is discontinued. Of interest, patients 
are advised to avoid fatty meals as they decrease the bioavail-
ability of voriconazole.
The major overall advantage of the azoles over ampho-
tericin B is their lower toxicity and availability for oral ad-
ministration. The co-administration of voriconazole with cal-
cineurin inhibitors is an alternative, although dose reduction of 
immunosuppressive drugs and close monitoring of drug levels 
is required [4].
Fluconazole
Fluconazole is a triazole antifungal drug used in the treatment 
and prevention of superficial and systemic fungal infections. 
Fluconazole is available in both oral and intravenous formu-
lations. It is the most common antifungal prophylactic agent.
However empirical treatment with fluconazole in neutro-
penic patients with suspected fungal infection may be inappro-
priate, because prior exposure, as treatment or prophylaxis, is 
associated with resistant candidal strains. In addition, flucona-
zole has limited activity against IA [24].
Itraconazole
Itraconazole has a wider spectrum than fluconazole. It is ac-
tive against both yeasts and molds. Boogaerts et al compared 
itraconazole with AmB-D in the empirical treatment of neutro-
penic sepsis. Itraconazole arm had fewer adverse events (5% 
versus 54%), and less withdrawal because of adverse events 
(19% versus 38%) and nephrotoxicity (5% versus 24%) when 
compared with AmB-D arm [25].
Side effects included headache, dizziness, raised hepatic 
transaminases, gastrointestinal symptoms, peripheral neuropa-
thy and allergic reactions.
Posaconazole
Posaconazole is the newest triazole antifungal agent, approved 
by FDA as prophylaxis for invasive Aspergillus and Candida 
infections in patients aged ≥ 13 years [26]. It is only found in 
oral formulation and predominantly eliminated in the feces, 
so dose adjustment is not required in renal and hepatic insuffi-
ciency. Posaconazole inhibits hepatic cytochrome P 450-3A4; 
therefore dose adjustments must be made to immunosuppres-
sive drugs [26].
The investigation involving 602 neutropenic patients with 
acute myelogenous leukemia or myelodysplastic syndrome 
undergoing myelosuppressive chemotherapy, compared 29 
days of prophylactic posaconazole with other azoles. Posacon-
azole was more effective in prevention of IA, when compared 
to other azoles (P < 0.001) [26].
Candins
The candins are a new class of antifungal agent that disrupts 
the biosynthesis glycan polymers in fungal cell wall. This 
specificity for glycan linkages makes it less toxic to human 
cells with a high therapeutic index for this class of compounds. 
With antifungal activity against Candida and Aspergillus spe-
cies and Pneumocystis carinii, these drugs have the potential 
use both in the treatment and in the prophylaxis of invasive 
fungal infections in solid organ transplant recipients [27].
Micafungin
Using a prospective, randomized, double blind comparative 
trial with 882 subjects, van Burik compared micafungin to flu-
conazole for prophylaxis against IFI. The overall success rate 
was 80% for micafungin when compared to 73.5% for flucona-
zole (95% CI: 0.9 - 12; P = 0.03). Moreover, treatment duration 
was shorter for micafungin and was effective in reducing the 
need for empirical treatment [27]. In conclusion, micafungin 
is as effective as fluconazole and poses as an alternative for 
antifungal prophylaxis.
Caspofungin
Caspofungin is licensed for the treatment of IA in adult pa-
tients who are refractory to or intolerant of AmB-D, lipid for-
mulations of amphotericin B and/or itraconazole. A favorable 
response was noted in 45% of 83 patients [17]. Caspofungin is 
also licensed for empirical therapy for presumed fungal infec-
tions (such as Candida or Aspergillus) in febrile neutropenic 
adults.
A comparison study was done between caspofungin and 
L-AmB in a randomized controlled trial involving over 1,000 
neutropenic patients. Caspofungin was found to be as effec-
tive, but generally better tolerated than L-AmB [28].
Anidulafungin
Anidulafungin is not metabolized by or eliminated through 
the liver or kidney. Consequently anidulafungin is free of in-
teractions with other drugs such as prednisone, cyclosporin, 
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tacrolimus, mofetil or sirolimus that are metabolized through 
the liver. Equally, dosage adjustments are not required in re-
nal impaired patients and in patients with severe liver disease. 
When compared to caspofungin, anidulafungin has a wider 
spectrum of action and lower toxicity profile. Although experi-
ence is still limited, and more studies need to be conducted, 
anidulafungin will be highly useful in the clinical management 
of solid organ transplant recipients.
Nystatin
Nystatin is a polyene antifungal medication that is active 
against molds and yeast infections, most notably Candida. To 
determine potential use of nystatin as a prophylactic or thera-
peutic drug in immunocompromised patients, 12 randomized 
trials were conducted comparing nystatin to placebo, untreated 
control group and fluconazole and amphotericin.
It was found that nystatin was similar to placebo in terms 
of potency (relative risk 0.85, 95% CI: 0.65 - 1.13) and inferior 
to fluconazole in preventing invasive fungal infection (relative 
risk 0.37, 0.15 - 0.91). Therefore, nystatin cannot be recom-
mended for prophylaxis or treatment of IFI [29].
Flucytosine
Flucytosine is used in the treatment of systemic fungal in-
fections caused by sensitive organisms mainly Candida and 
Cryptococcus. Flucytosine is known for rapid emergence of 
resistance when used alone; therefore it is given in combina-
tion with another antifungal agent.
Side effects include nausea, diarrhea, hepatotoxicity and 
bone marrow suppression. All are reversible on discontinua-
tion of the drug.
Human Interferon (IFN)-γ Therapy
Armstrong-James’s study involving 10 renal allograft recipi-
ents with proven or probable invasive fungal diseases was 
studied over a 5-year period [29]. As all renal transplant pa-
tients were taking immunosuppressive therapy, the IFN-γ lev-
els were much lower in stable transplants than in healthy con-
trols (P < 0.001).
But comparing stable renal allograft recipients with re-
nal allograft recipients who had developed an invasive fungal 
disease revealed patients with invasive fungal diseases failed 
to mount an adequate IFN-γ response to the fungal infection 
[30].
Based on the findings, it may be concluded that T cell-
based immune responses are important for protective immu-
nity against invasive fungal diseases in transplant patients.
Additionally, a separate study was conducted by the same 
author, looking at the potential benefits of adding adjunctive 
human IFN-γ therapy to on seven renal transplant patients who 
developed life-threatening, disseminated IFIs refractory to 
conventional antifungal drug therapy [31].
Six out of seven patients had a promising response to 6 
weeks of human IFN-γ therapy. Furthermore, long-term pa-
tient follow-up reported no relapse history. Currently prolong 
antifungal therapy in IFI patient can be very expensive. In con-
trast, the 6-week course of IFN-γ injections will be less expen-
sive with an approximate cost of $2,600 [31].
Therefore, these observations provide a possible expla-
nation for the therapeutic benefit of adjunctive human IFN-γ 
therapy in renal allograft recipients with invasive fungal dis-
eases. Till date, research and clinical studies with the implica-
tions of adjunctive human IFN-γ therapy are still limited, and 
more studies need to be conducted.
Granulocyte-Colony Stimulating Factor (G-
CSF)
The use of G-CSF and granulocyte monocyte-colony stimulat-
ing factor (GM-CSF) can shorten the period of neutropenia, 
and improve the overall immune status of the patient.
Antifungal Prophylaxis
Study was conducted by Playford to determine the effects of 
antifungal prophylaxis in solid organ transplant recipients. 
Fourteen randomized controlled trials were studied with 1,497 
randomized subjects [32].
Antifungal prophylaxis failed to show a reduction in mor-
tality (RR 0.90, 95% CI: 0.57 - 1.44). However, a significant 
reduction in IFIs was demonstrated in liver transplant recipi-
ents using fluconazole (RR 0.28, 95% CI: 0.13 - 0.57). A con-
clusion in renal transplant recipients could not be drawn due to 
the insufficient data [32].
One should take into account the high mortality rates of 
IFI in transplant recipients, or situations where the individual 
risk is great, antifungal prophylaxis should be considered em-
pirically. The duration of prophylaxis is currently unknown, 
but it has been recommended that this should cover the period 
of neutropenia [22]. An approach to antifungal prophylaxis for 
organ transplant recipients is shown in Table 2 [33].
Voriconazole is approved by the FDA for the treatment 
of aspergillosis. This azole offers broader filamentous mold 
activity than either fluconazole or itraconazole but has no ac-
tivity against the agents of mucormycosis. In addition, vori-
conazole is a significant inhibitor of the cytochrome P450 
enzymes.
The use of fluconazole prophylaxis (400 mg/day) has 
been shown to reduce the incidence and severity of Candida 
infections [34]. Fluconazole does not have activity against 
filamentous fungi. Drug interactions with calcineurin inhibi-
tor are variable; dose readjustment is essential to prevent graft 
rejection.
Itraconazole (2.5 mg/kg twice daily) has been compared 
to fluconazole in this group of patients and found to be com-
parable in preventing Candida infection but more effective in 
preventing mold infection [35].
Amphotericin B (both regular and lipid formulations) can 
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be used for the prevention of invasive fungal infections. How-
ever, low dose amphoteracin B regimens as a prophylaxis for 
IA have been futile [36].
Intravascular lines
Any intravascular cannulae may act as the port of entry for 
fungal infections. A reduction of overall mortality from can-
didemia following cannula removal was 40%, compared with 
86.9% when cannulae were not removed. Intravascular can-
nulae removal therefore is recommended in the treatment of 
candidemias whenever possible [37].
Vaccines
Due to the immunocompromised state of transplant recipients, 
they do not respond to vaccines when compared to healthy in-
dividuals. Therefore all transplant candidates must have their 
vaccine status assessed and updated as per the standard rec-
ommendations by Centers for Disease Control and Prevention. 
Patients who are not immune to varicella should also be vacci-
nated, with a minimum of 2 - 4 weeks series completion before 
transplantation [1].
Environmental
In areas with high incidence of infection due to aspergillosis or 
Candida species, both fungal prophylaxis and epidemiological 
protection (e.g. HEPA filtered air supply in hospital) may be 
utilized.
Cases
Case 1
A 58-year-old female with an extensive past medical history 
of multiple comorbidities with renal transplant done 5 years 
ago, taking cellcept (myophenolate), prograft (tacrolimus) and 
prednisolone was admitted with progressive worsening dysp-
nea associated with non-resolving cough and low grade fever. 
She had a bronchoscopy done 2 months back that revealed as-
pergillosis fumigatus.
On physical examination, she had a temperate of 100.8 
°F with bilateral rhonchi and coarse breath sounds. She was 
immediately admitted to the ICU, and intubated for airway 
protection until antibiotics and antifungal agents took effect.
Her initial set of lab showed elevated WBC count of 41.45 
and a Cr of 1.14. Aspergillus Ab was negative. Blood and urine 
culture was negative. Urine RME revealed few yeast.
A chest X-ray was done and reported left upper lobe opac-
ity.
A CT chest showed multiple focal air space opacity (Lt > 
Rt) and small bilateral pleural effusion.
Patient was started on levofloxacin, amikacin, meropen-
em, and voriconalzole among her usual medications. Her pro-
graft dose was reduced from 2 mg to 1 mg.
Bronchoscopy was done 9 days after admission. Broncho-
alveolar lavage from the left lower lobe did not identify any 
fungus and fungal Ag markers were negative. Right thoracos-
copy wedge biopsy was done, but all tests were normal.
The patient responded well to the treatment and was suc-
cessfully extubated. The WBC count came down to normal 
levels. She was able to ambulate without the need for oxygen. 
Table 2.  Suggested Approach to Antifungal Prophylaxis for Organ Transplant Recipients [33]
Transplant 
organ
Targeted 
pathogen High-risk characteristics Agent Duration
Liver Aspergillus Poor allograft function; fulminant hepatic  
failure pretransplantation; reexploration  
or retransplantation; hemodialysis; isolation of  
aspergillus from any site
Lipid AmB 1 - 4 weeks
Liver Candida Repeated operation; higher intraoperative  
transfusion requirements; longer operation  
time; renal failure; ICU stay
Fluconazole
alternative: 
 echinocandin 
or lipid AmB
1 - 4 weeks
Lung Aspergillus Airway specimen cultures positive for  
aspergillus, particularly for patients with  
rejection or poor graft function;  
increased immunosuppression
Itraconazole or  
voriconazole or  
lipid-AmB A (full dose 
I/V) ± nebulized AmB
Depends on CT findings and  
clearance of sputum cultures,  
appearance of tracheal anastomosis.
1 to 6 months
Pancreas Candida All procedures (risk increased with enteric 
drainage, anastomotic leak, pancreas 
 transplantation after kidney transplantation,  
pancreatitis)
Fluconazole  
alternative:  
echinocandin or 
lipid AmB
4 weeks
Bowel Candida All procedures (risk increased with peritonitis  
or leaks, reexploration, renal failure, ischemia,  
CMV infection, parenteral nutrition)
Fluconazole
alternative: 
 echinocandin 
or lipid AmB
2 - 4 weeks
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She was discharged with cellcept and prograft and she was 
asked to continue voriconalzole for 3 weeks more.
Case 2
A 56-year-old female from a nursing home, with multiple co-
morbidities with a significant past medical history of renal 
transplant 2 months back and taking cellcept (myophenolate), 
prograft (tacrolimus) and prednisolone, comes to the ER with 
the shortness of breath and cough associated with green spu-
tum for 1 day and rectal bleeding.
On examination, the patient was moderately distressed 
and cachectic. She was hypotensive (85/50 mm Hg) with a 
pulse of 92 bpm. The patient was immediately resuscitated, 
appropriate labs were ordered and patient was started on em-
pirical antibiotics, vancomycin and cefepime.
On admission, CBC was significant for neutropenia with 
a total WBC count of 2.17, Hb of 8.2 and Hct of 27.2. A cell 
count 2 days prior to her admission was normal. Her fall in 
counts may be due to sepsis or side effect of cellcept.
Chest X-ray showed right lower lobe consolidation. Chest 
CT reported bilateral basilar and lower lobe consolidation and 
small right apical pneumonia. CT of abdomen was suggestive 
of sigmoid colitis.
Echo showed possible tricuspid vegetation, which could 
be a source for the patient’s septicemia.
Bronchoscopy was done the next day. Diffuse inflamma-
tion was noted on the tracheobronchial tree and bronchoalveo-
lar lavage testing was positive for clusters of septate fungal 
organisms suggestive of aspergillosis; Candida was also iden-
tified. BAL culture grew Pseudomonas aeruginosa.
A repeat CBC on the second day of admission revealed 
pancytopenia. Patient was treated with valgancyclovir, van-
comycin, meropenem and neupogen. Her cellcept was put 
on hold, until the cell count stabilizes. She was transferred to 
Mount Sinai after 2 days from admission, where she was diag-
nosed with aspergillosis, and was treated accordingly.
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